> top > docs > PMC:2674207 > spans > 12350-13140 > annotations

PMC:2674207 / 12350-13140 JSONTXT

Annnotations TAB JSON ListView MergeView

2_test

Id Subject Object Predicate Lexical cue
19436703-15860753-86274485 223-225 15860753 denotes 34
T86367 223-225 15860753 denotes 34

pmc-enju-pas

Id Subject Object Predicate Lexical cue
T3675 0-12 NN denotes Participants
T3676 13-16 CC denotes and
T3677 17-22 NN denotes Study
T3678 23-29 NN denotes Design
T3679 30-32 PRP denotes We
T3680 33-40 VB denotes studied
T3681 41-49 NN denotes patients
T3682 50-54 IN denotes with
T3683 55-59 JJ denotes mild
T3684 60-66 NN denotes asthma
T3685 67-70 WP denotes who
T3686 71-75 VB denotes were
T3687 76-79 RB denotes not
T3688 80-87 VB denotes treated
T3689 88-92 IN denotes with
T3690 93-100 VB denotes inhaled
T3691 101-116 NN denotes corticosteroids
T3692 117-120 WP denotes who
T3693 121-124 VB denotes had
T3694 125-129 VB denotes been
T3695 130-138 VB denotes included
T3696 139-141 IN denotes in
T3697 142-143 DT denotes a
T3698 144-154 RB denotes previously
T3699 155-163 VB denotes reported
T3700 164-176 JJ denotes double-blind
T3701 176-177 -COMMA- denotes ,
T3702 178-196 JJ denotes placebo-controlled
T3703 196-197 -COMMA- denotes ,
T3704 198-207 JJ denotes crossover
T3705 208-213 NN denotes study
T3706 214-218 IN denotes with
T3707 219-221 NN denotes FP
T3708 222-223 -LRB- denotes [
T3709 223-225 CD denotes 34
T3710 225-226 -RRB- denotes ]
T3711 228-233 CD denotes Seven
T3712 234-242 NN denotes patients
T3713 243-247 IN denotes with
T3714 248-252 JJ denotes mild
T3715 253-259 NN denotes asthma
T3716 260-267 VB denotes entered
T3717 268-271 DT denotes the
T3718 272-277 NN denotes study
T3719 278-281 CC denotes and
T3720 282-286 VB denotes were
T3721 287-297 VB denotes randomized
T3722 298-300 TO denotes to
T3723 301-308 VB denotes receive
T3724 309-310 DT denotes a
T3725 311-317 JJ denotes single
T3726 318-328 NN denotes inhalation
T3727 329-331 IN denotes of
T3728 332-334 NN denotes FP
T3729 335-336 -LRB- denotes (
T3730 336-339 CD denotes 100
T3731 340-343 CC denotes and
T3732 344-347 CD denotes 500
T3733 348-350 NN denotes µg
T3734 350-351 -RRB- denotes )
T3735 352-354 CC denotes or
T3736 355-356 DT denotes a
T3737 357-364 JJ denotes matched
T3738 365-372 NN denotes placebo
T3739 373-380 NN denotes control
T3740 381-384 IN denotes via
T3741 385-386 DT denotes a
T3742 387-393 NN denotes spacer
T3743 394-401 NN denotes chamber
T3744 401-402 -COMMA- denotes ,
T3745 403-406 CC denotes and
T3746 407-410 DT denotes the
T3747 411-416 JJ denotes other
T3748 417-426 NN denotes treatment
T3749 427-430 VB denotes was
T3750 431-436 VB denotes given
T3751 437-442 IN denotes after
T3752 443-444 DT denotes a
T3753 445-453 JJ denotes wash-out
T3754 454-460 NN denotes period
T3755 461-463 IN denotes of
T3756 464-466 IN denotes at
T3757 467-472 JJ denotes least
T3758 473-474 CD denotes 6
T3759 475-476 NN denotes d
T3760 478-483 NN denotes Blood
T3761 484-487 VB denotes was
T3762 488-493 VB denotes taken
T3763 494-497 IN denotes for
T3764 498-509 NN denotes preparation
T3765 510-512 IN denotes of
T3766 513-518 NN denotes PBMCs
T3767 519-521 IN denotes at
T3768 522-523 CD denotes 1
T3769 524-527 CC denotes and
T3770 528-529 CD denotes 2
T3771 530-531 NN denotes h
T3772 532-537 IN denotes after
T3773 538-542 NN denotes drug
T3774 543-557 NN denotes administration
T3775 559-562 DT denotes All
T3776 563-571 NN denotes patients
T3777 572-576 VB denotes gave
T3778 577-585 VB denotes informed
T3779 586-593 NN denotes consent
T3780 594-597 CC denotes and
T3781 598-601 DT denotes the
T3782 602-607 NN denotes study
T3783 608-611 VB denotes was
T3784 612-620 VB denotes approved
T3785 621-623 IN denotes by
T3786 624-627 DT denotes the
T3787 628-634 NNP denotes Ethics
T3788 635-644 NNP denotes Committee
T3789 645-647 IN denotes of
T3790 648-651 DT denotes the
T3791 652-657 NNP denotes Royal
T3792 658-666 NNP denotes Brompton
T3793 667-670 CC denotes and
T3794 671-680 NNP denotes Harefield
T3795 681-690 NNP denotes Hospitals
T3796 691-694 NNP denotes NHS
T3797 695-701 NNP denotes Trust.
T3798 702-705 DT denotes The
T3799 706-714 JJ denotes clinical
T3800 715-720 NN denotes study
T3801 721-724 VB denotes was
T3802 725-734 VB denotes conducted
T3803 735-741 IN denotes before
T3804 742-745 DT denotes the
T3805 746-757 NN denotes requirement
T3806 758-761 IN denotes for
T3807 762-770 NNP denotes Clinical
T3808 771-776 NNP denotes Trial
T3809 777-789 NNP denotes Registration
R3148 T3675 T3676 arg1Of Participants,and
R3149 T3678 T3676 arg2Of Design,and
R3150 T3678 T3677 arg1Of Design,Study
R3151 T3679 T3680 arg1Of We,studied
R3152 T3680 T3701 arg1Of studied,","
R3153 T3680 T3708 arg1Of studied,[
R3154 T3681 T3680 arg2Of patients,studied
R3155 T3681 T3682 arg1Of patients,with
R3156 T3681 T3685 arg1Of patients,who
R3157 T3681 T3686 arg1Of patients,were
R3158 T3681 T3688 arg2Of patients,treated
R3159 T3684 T3682 arg2Of asthma,with
R3160 T3684 T3683 arg1Of asthma,mild
R3161 T3688 T3686 arg2Of treated,were
R3162 T3688 T3687 arg1Of treated,not
R3163 T3688 T3689 arg1Of treated,with
R3164 T3691 T3689 arg2Of corticosteroids,with
R3165 T3691 T3690 arg2Of corticosteroids,inhaled
R3166 T3691 T3692 arg1Of corticosteroids,who
R3167 T3691 T3693 arg1Of corticosteroids,had
R3168 T3691 T3694 arg1Of corticosteroids,been
R3169 T3691 T3695 arg2Of corticosteroids,included
R3170 T3695 T3693 arg2Of included,had
R3171 T3695 T3694 arg2Of included,been
R3172 T3695 T3696 arg1Of included,in
R3173 T3699 T3698 arg1Of reported,previously
R3174 T3700 T3696 arg2Of double-blind,in
R3175 T3700 T3697 arg1Of double-blind,a
R3176 T3700 T3699 arg1Of double-blind,reported
R3177 T3702 T3703 arg1Of placebo-controlled,","
R3178 T3704 T3703 arg2Of crossover,","
R3179 T3705 T3680 arg3Of study,studied
R3180 T3705 T3702 arg1Of study,placebo-controlled
R3181 T3705 T3704 arg1Of study,crossover
R3182 T3705 T3706 arg1Of study,with
R3183 T3707 T3706 arg2Of FP,with
R3184 T3709 T3708 arg2Of 34,[
R3185 T3710 T3708 arg3Of ],[
R3186 T3712 T3711 arg1Of patients,Seven
R3187 T3712 T3713 arg1Of patients,with
R3188 T3712 T3716 arg1Of patients,entered
R3189 T3712 T3720 arg1Of patients,were
R3190 T3712 T3721 arg2Of patients,randomized
R3191 T3712 T3723 arg1Of patients,receive
R3192 T3715 T3713 arg2Of asthma,with
R3193 T3715 T3714 arg1Of asthma,mild
R3194 T3716 T3719 arg1Of entered,and
R3195 T3718 T3716 arg2Of study,entered
R3196 T3718 T3717 arg1Of study,the
R3197 T3719 T3745 arg1Of and,and
R3198 T3721 T3719 arg2Of randomized,and
R3199 T3721 T3720 arg2Of randomized,were
R3200 T3723 T3721 arg3Of receive,randomized
R3201 T3723 T3722 arg1Of receive,to
R3202 T3723 T3740 arg1Of receive,via
R3203 T3726 T3724 arg1Of inhalation,a
R3204 T3726 T3725 arg1Of inhalation,single
R3205 T3726 T3727 arg1Of inhalation,of
R3206 T3726 T3735 arg1Of inhalation,or
R3207 T3728 T3727 arg2Of FP,of
R3208 T3728 T3729 arg1Of FP,(
R3209 T3730 T3731 arg1Of 100,and
R3210 T3732 T3731 arg2Of 500,and
R3211 T3733 T3729 arg2Of µg,(
R3212 T3733 T3730 arg1Of µg,100
R3213 T3733 T3732 arg1Of µg,500
R3214 T3734 T3729 arg3Of ),(
R3215 T3735 T3723 arg2Of or,receive
R3216 T3739 T3735 arg2Of control,or
R3217 T3739 T3736 arg1Of control,a
R3218 T3739 T3737 arg1Of control,matched
R3219 T3739 T3738 arg1Of control,placebo
R3220 T3743 T3740 arg2Of chamber,via
R3221 T3743 T3741 arg1Of chamber,a
R3222 T3743 T3742 arg1Of chamber,spacer
R3223 T3745 T3744 arg1Of and,","
R3224 T3748 T3746 arg1Of treatment,the
R3225 T3748 T3747 arg1Of treatment,other
R3226 T3748 T3749 arg1Of treatment,was
R3227 T3748 T3750 arg2Of treatment,given
R3228 T3750 T3745 arg2Of given,and
R3229 T3750 T3749 arg2Of given,was
R3230 T3750 T3751 arg1Of given,after
R3231 T3754 T3751 arg2Of period,after
R3232 T3754 T3752 arg1Of period,a
R3233 T3754 T3753 arg1Of period,wash-out
R3234 T3754 T3755 arg1Of period,of
R3235 T3758 T3756 arg1Of 6,at
R3236 T3758 T3757 arg1Of 6,least
R3237 T3759 T3755 arg2Of d,of
R3238 T3759 T3758 arg1Of d,6
R3239 T3760 T3761 arg1Of Blood,was
R3240 T3760 T3762 arg2Of Blood,taken
R3241 T3762 T3761 arg2Of taken,was
R3242 T3762 T3763 arg1Of taken,for
R3243 T3764 T3763 arg2Of preparation,for
R3244 T3764 T3765 arg1Of preparation,of
R3245 T3764 T3767 arg1Of preparation,at
R3246 T3766 T3765 arg2Of PBMCs,of
R3247 T3768 T3769 arg1Of 1,and
R3248 T3770 T3769 arg2Of 2,and
R3249 T3771 T3767 arg2Of h,at
R3250 T3771 T3768 arg1Of h,1
R3251 T3771 T3770 arg1Of h,2
R3252 T3771 T3772 arg1Of h,after
R3253 T3774 T3772 arg2Of administration,after
R3254 T3774 T3773 arg1Of administration,drug
R3255 T3776 T3775 arg1Of patients,All
R3256 T3776 T3777 arg1Of patients,gave
R3257 T3776 T3801 arg1Of patients,was
R3258 T3776 T3802 arg2Of patients,conducted
R3259 T3777 T3780 arg1Of gave,and
R3260 T3779 T3777 arg2Of consent,gave
R3261 T3779 T3778 arg2Of consent,informed
R3262 T3782 T3781 arg1Of study,the
R3263 T3782 T3783 arg1Of study,was
R3264 T3782 T3784 arg2Of study,approved
R3265 T3784 T3783 arg2Of approved,was
R3266 T3788 T3786 arg1Of Committee,the
R3267 T3788 T3787 arg1Of Committee,Ethics
R3268 T3788 T3789 arg1Of Committee,of
R3269 T3788 T3793 arg1Of Committee,and
R3270 T3792 T3789 arg2Of Brompton,of
R3271 T3792 T3790 arg1Of Brompton,the
R3272 T3792 T3791 arg1Of Brompton,Royal
R3273 T3793 T3784 arg1Of and,approved
R3274 T3793 T3785 arg2Of and,by
R3275 T3797 T3794 arg1Of Trust.,Harefield
R3276 T3797 T3795 arg1Of Trust.,Hospitals
R3277 T3797 T3796 arg1Of Trust.,NHS
R3278 T3800 T3793 arg2Of study,and
R3279 T3800 T3797 arg1Of study,Trust.
R3280 T3800 T3798 arg1Of study,The
R3281 T3800 T3799 arg1Of study,clinical
R3282 T3802 T3780 arg2Of conducted,and
R3283 T3802 T3783 modOf conducted,was
R3284 T3802 T3801 arg2Of conducted,was
R3285 T3802 T3803 arg1Of conducted,before
R3286 T3805 T3803 arg2Of requirement,before
R3287 T3805 T3804 arg1Of requirement,the
R3288 T3805 T3806 arg1Of requirement,for
R3289 T3809 T3806 arg2Of Registration,for
R3290 T3809 T3807 arg1Of Registration,Clinical
R3291 T3809 T3808 arg1Of Registration,Trial

bionlp-st-ge-2016-spacy-parsed

Id Subject Object Predicate Lexical cue
T3810 0-12 NNS denotes Participants
T3811 13-16 CC denotes and
T3812 17-22 NNP denotes Study
T3813 23-29 NNP denotes Design
T3814 30-32 PRP denotes We
T3815 33-40 VBD denotes studied
T3816 41-49 NNS denotes patients
T3817 50-54 IN denotes with
T3818 55-59 JJ denotes mild
T3819 60-66 NN denotes asthma
T3820 67-70 WP denotes who
T3821 71-75 VBD denotes were
T3822 76-79 RB denotes not
T3823 80-87 VBN denotes treated
T3824 88-92 IN denotes with
T3825 93-100 JJ denotes inhaled
T3826 101-116 NNS denotes corticosteroids
T3827 117-120 WP denotes who
T3828 121-124 VBD denotes had
T3829 125-129 VBN denotes been
T3830 130-138 VBN denotes included
T3831 139-141 IN denotes in
T3832 142-143 DT denotes a
T3833 144-154 RB denotes previously
T3834 155-163 VBN denotes reported
T3835 164-176 NN denotes double-blind
T3836 176-177 , denotes ,
T3837 178-196 JJ denotes placebo-controlled
T3838 196-197 , denotes ,
T3839 198-207 JJ denotes crossover
T3840 208-213 NN denotes study
T3841 214-218 IN denotes with
T3842 219-221 NNP denotes FP
T3843 222-223 NNP denotes [
T3844 223-225 CD denotes 34
T3845 225-226 NNP denotes ]
T3846 226-227 . denotes .
T3847 228-233 CD denotes Seven
T3848 234-242 NNS denotes patients
T3849 243-247 IN denotes with
T3850 248-252 JJ denotes mild
T3851 253-259 NN denotes asthma
T3852 260-267 VBD denotes entered
T3853 268-271 DT denotes the
T3854 272-277 NN denotes study
T3855 278-281 CC denotes and
T3856 282-286 VBD denotes were
T3857 287-297 VBN denotes randomized
T3858 298-300 TO denotes to
T3859 301-308 VB denotes receive
T3860 309-310 DT denotes a
T3861 311-317 JJ denotes single
T3862 318-328 NN denotes inhalation
T3863 329-331 IN denotes of
T3864 332-334 NNP denotes FP
T3865 335-336 -LRB- denotes (
T3866 336-339 CD denotes 100
T3867 340-343 CC denotes and
T3868 344-347 CD denotes 500
T3869 348-350 NN denotes µg
T3870 350-351 -RRB- denotes )
T3871 352-354 CC denotes or
T3872 355-356 DT denotes a
T3873 357-364 VBN denotes matched
T3874 365-372 NN denotes placebo
T3875 373-380 NN denotes control
T3876 381-384 IN denotes via
T3877 385-386 DT denotes a
T3878 387-393 NN denotes spacer
T3879 394-401 NN denotes chamber
T3880 401-402 , denotes ,
T3881 403-406 CC denotes and
T3882 407-410 DT denotes the
T3883 411-416 JJ denotes other
T3884 417-426 NN denotes treatment
T3885 427-430 VBD denotes was
T3886 431-436 VBN denotes given
T3887 437-442 IN denotes after
T3888 443-444 DT denotes a
T3889 445-453 JJ denotes wash-out
T3890 454-460 NN denotes period
T3891 461-463 IN denotes of
T3892 464-466 IN denotes at
T3893 467-472 JJS denotes least
T3894 473-474 CD denotes 6
T3895 475-477 NN denotes d.
T3896 478-483 NNP denotes Blood
T3897 484-487 VBD denotes was
T3898 488-493 VBN denotes taken
T3899 494-497 IN denotes for
T3900 498-509 NN denotes preparation
T3901 510-512 IN denotes of
T3902 513-518 NNS denotes PBMCs
T3903 519-521 IN denotes at
T3904 522-523 CD denotes 1
T3905 524-527 CC denotes and
T3906 528-529 CD denotes 2
T3907 530-531 NN denotes h
T3908 532-537 IN denotes after
T3909 538-542 NN denotes drug
T3910 543-557 NN denotes administration
T3911 557-558 . denotes .
T3912 559-562 DT denotes All
T3913 563-571 NNS denotes patients
T3914 572-576 VBD denotes gave
T3915 577-585 VBN denotes informed
T3916 586-593 NN denotes consent
T3917 594-597 CC denotes and
T3918 598-601 DT denotes the
T3919 602-607 NN denotes study
T3920 608-611 VBD denotes was
T3921 612-620 VBN denotes approved
T3922 621-623 IN denotes by
T3923 624-627 DT denotes the
T3924 628-634 NNPS denotes Ethics
T3925 635-644 NNP denotes Committee
T3926 645-647 IN denotes of
T3927 648-651 DT denotes the
T3928 652-657 NNP denotes Royal
T3929 658-666 NNP denotes Brompton
T3930 667-670 CC denotes and
T3931 671-680 NNP denotes Harefield
T3932 681-690 NNPS denotes Hospitals
T3933 691-694 NNP denotes NHS
T3934 695-700 NNP denotes Trust
T3935 700-701 . denotes .
T3936 702-705 DT denotes The
T3937 706-714 JJ denotes clinical
T3938 715-720 NN denotes study
T3939 721-724 VBD denotes was
T3940 725-734 VBN denotes conducted
T3941 735-741 IN denotes before
T3942 742-745 DT denotes the
T3943 746-757 NN denotes requirement
T3944 758-761 IN denotes for
T3945 762-770 NNP denotes Clinical
T3946 771-776 NNP denotes Trial
T3947 777-789 NNP denotes Registration
T3948 789-790 . denotes .
R3292 T3810 T3815 npadvmod Participants,studied
R3293 T3811 T3810 cc and,Participants
R3294 T3812 T3813 compound Study,Design
R3295 T3813 T3810 conj Design,Participants
R3296 T3814 T3815 nsubj We,studied
R3297 T3815 T3815 ROOT studied,studied
R3298 T3816 T3815 dobj patients,studied
R3299 T3817 T3816 prep with,patients
R3300 T3818 T3819 amod mild,asthma
R3301 T3819 T3817 pobj asthma,with
R3302 T3820 T3823 nsubjpass who,treated
R3303 T3821 T3823 auxpass were,treated
R3304 T3822 T3823 neg not,treated
R3305 T3823 T3816 relcl treated,patients
R3306 T3824 T3823 prep with,treated
R3307 T3825 T3826 amod inhaled,corticosteroids
R3308 T3826 T3824 pobj corticosteroids,with
R3309 T3827 T3830 nsubjpass who,included
R3310 T3828 T3830 aux had,included
R3311 T3829 T3830 auxpass been,included
R3312 T3830 T3826 relcl included,corticosteroids
R3313 T3831 T3830 prep in,included
R3314 T3832 T3840 det a,study
R3315 T3833 T3834 advmod previously,reported
R3316 T3834 T3835 amod reported,double-blind
R3317 T3835 T3840 amod double-blind,study
R3318 T3836 T3840 punct ",",study
R3319 T3837 T3840 amod placebo-controlled,study
R3320 T3838 T3840 punct ",",study
R3321 T3839 T3840 amod crossover,study
R3322 T3840 T3831 pobj study,in
R3323 T3841 T3840 prep with,study
R3324 T3842 T3843 compound FP,[
R3325 T3843 T3841 pobj [,with
R3326 T3844 T3845 nummod 34,]
R3327 T3845 T3843 appos ],[
R3328 T3846 T3815 punct .,studied
R3329 T3847 T3848 nummod Seven,patients
R3330 T3848 T3852 nsubj patients,entered
R3331 T3849 T3848 prep with,patients
R3332 T3850 T3851 amod mild,asthma
R3333 T3851 T3849 pobj asthma,with
R3334 T3852 T3852 ROOT entered,entered
R3335 T3853 T3854 det the,study
R3336 T3854 T3852 dobj study,entered
R3337 T3855 T3852 cc and,entered
R3338 T3856 T3857 auxpass were,randomized
R3339 T3857 T3852 conj randomized,entered
R3340 T3858 T3859 aux to,receive
R3341 T3859 T3857 xcomp receive,randomized
R3342 T3860 T3862 det a,inhalation
R3343 T3861 T3862 amod single,inhalation
R3344 T3862 T3859 dobj inhalation,receive
R3345 T3863 T3862 prep of,inhalation
R3346 T3864 T3863 pobj FP,of
R3347 T3865 T3864 punct (,FP
R3348 T3866 T3864 nummod 100,FP
R3349 T3867 T3864 cc and,FP
R3350 T3868 T3869 nummod 500,µg
R3351 T3869 T3864 conj µg,FP
R3352 T3870 T3869 punct ),µg
R3353 T3871 T3869 cc or,µg
R3354 T3872 T3875 det a,control
R3355 T3873 T3875 amod matched,control
R3356 T3874 T3875 compound placebo,control
R3357 T3875 T3869 conj control,µg
R3358 T3876 T3859 prep via,receive
R3359 T3877 T3879 det a,chamber
R3360 T3878 T3879 compound spacer,chamber
R3361 T3879 T3876 pobj chamber,via
R3362 T3880 T3857 punct ",",randomized
R3363 T3881 T3857 cc and,randomized
R3364 T3882 T3884 det the,treatment
R3365 T3883 T3884 amod other,treatment
R3366 T3884 T3886 nsubjpass treatment,given
R3367 T3885 T3886 auxpass was,given
R3368 T3886 T3857 conj given,randomized
R3369 T3887 T3898 mark after,taken
R3370 T3888 T3890 det a,period
R3371 T3889 T3890 amod wash-out,period
R3372 T3890 T3898 nsubjpass period,taken
R3373 T3891 T3890 prep of,period
R3374 T3892 T3893 advmod at,least
R3375 T3893 T3894 advmod least,6
R3376 T3894 T3895 nummod 6,d.
R3377 T3895 T3896 compound d.,Blood
R3378 T3896 T3891 pobj Blood,of
R3389 T3907 T3898 conj h,taken
R3390 T3908 T3907 prep after,h
R3391 T3909 T3910 compound drug,administration
R3392 T3910 T3908 pobj administration,after
R3393 T3911 T3852 punct .,entered
R3394 T3912 T3913 det All,patients
R3395 T3913 T3914 nsubj patients,gave
R3396 T3914 T3914 ROOT gave,gave
R3397 T3915 T3916 amod informed,consent
R3398 T3916 T3914 dobj consent,gave
R3399 T3917 T3916 cc and,consent
R3400 T3918 T3919 det the,study
R3401 T3919 T3921 nsubjpass study,approved
R3402 T3920 T3921 auxpass was,approved
R3403 T3921 T3914 conj approved,gave
R3404 T3922 T3921 agent by,approved
R3405 T3923 T3925 det the,Committee
R3406 T3924 T3925 compound Ethics,Committee
R3407 T3925 T3922 pobj Committee,by
R3408 T3926 T3925 prep of,Committee
R3409 T3927 T3929 det the,Brompton
R3410 T3928 T3929 compound Royal,Brompton
R3411 T3929 T3926 pobj Brompton,of
R3412 T3930 T3929 cc and,Brompton
R3413 T3931 T3934 compound Harefield,Trust
R3414 T3932 T3934 compound Hospitals,Trust
R3415 T3933 T3934 compound NHS,Trust
R3416 T3934 T3929 conj Trust,Brompton
R3417 T3935 T3921 punct .,approved
R3418 T3936 T3938 det The,study
R3419 T3937 T3938 amod clinical,study
R3420 T3938 T3940 nsubjpass study,conducted
R3421 T3939 T3940 auxpass was,conducted
R3422 T3940 T3940 ROOT conducted,conducted
R3423 T3941 T3940 prep before,conducted
R3424 T3942 T3943 det the,requirement
R3425 T3943 T3941 pobj requirement,before
R3426 T3944 T3943 prep for,requirement
R3427 T3945 T3947 compound Clinical,Registration
R3428 T3946 T3947 compound Trial,Registration
R3429 T3947 T3944 pobj Registration,for
R3430 T3948 T3940 punct .,conducted
R3379 T3897 T3898 auxpass was,taken
R3380 T3898 T3886 advcl taken,given
R3381 T3899 T3898 prep for,taken
R3382 T3900 T3899 pobj preparation,for
R3383 T3901 T3900 prep of,preparation
R3384 T3902 T3901 pobj PBMCs,of
R3385 T3903 T3898 prep at,taken
R3386 T3904 T3903 pobj 1,at
R3387 T3905 T3898 cc and,taken
R3388 T3906 T3907 nummod 2,h

sentences

Id Subject Object Predicate Lexical cue
T3670 0-29 Sentence denotes Participants and Study Design
T3671 30-227 Sentence denotes We studied patients with mild asthma who were not treated with inhaled corticosteroids who had been included in a previously reported double-blind, placebo-controlled, crossover study with FP [34].
T3672 228-477 Sentence denotes Seven patients with mild asthma entered the study and were randomized to receive a single inhalation of FP (100 and 500 µg) or a matched placebo control via a spacer chamber, and the other treatment was given after a wash-out period of at least 6 d.
T3673 478-558 Sentence denotes Blood was taken for preparation of PBMCs at 1 and 2 h after drug administration.
T3674 559-790 Sentence denotes All patients gave informed consent and the study was approved by the Ethics Committee of the Royal Brompton and Harefield Hospitals NHS Trust. The clinical study was conducted before the requirement for Clinical Trial Registration.
T79 0-29 Sentence denotes Participants and Study Design
T80 30-227 Sentence denotes We studied patients with mild asthma who were not treated with inhaled corticosteroids who had been included in a previously reported double-blind, placebo-controlled, crossover study with FP [34].
T81 228-477 Sentence denotes Seven patients with mild asthma entered the study and were randomized to receive a single inhalation of FP (100 and 500 µg) or a matched placebo control via a spacer chamber, and the other treatment was given after a wash-out period of at least 6 d.
T82 478-558 Sentence denotes Blood was taken for preparation of PBMCs at 1 and 2 h after drug administration.
T83 559-701 Sentence denotes All patients gave informed consent and the study was approved by the Ethics Committee of the Royal Brompton and Harefield Hospitals NHS Trust.
T84 702-790 Sentence denotes The clinical study was conducted before the requirement for Clinical Trial Registration.

ICD10

Id Subject Object Predicate Lexical cue
T3954 60-66 http://purl.bioontology.org/ontology/ICD10/J45.9 denotes asthma
T3955 253-259 http://purl.bioontology.org/ontology/ICD10/J45.9 denotes asthma
T3956 60-66 http://purl.bioontology.org/ontology/ICD10/J45 denotes asthma
T3957 253-259 http://purl.bioontology.org/ontology/ICD10/J45 denotes asthma